Preclinical multimodality phantom design for quality assurance of tumor size measurement
Open Access
- 30 September 2011
- journal article
- Published by Springer Nature in BMC Medical Physics
- Vol. 11 (1) , 1
Abstract
Background: Evaluation of changes in tumor size from images acquired by ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy. Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing. Methods: Three phantoms (Gammex/UTHSCSA Mark 1, Gammex/UTHSCSA Mark 2 and UTHSCSA multimodality tumor measurement phantom) containing tumor-simulating test objects were designed and constructed. All three phantoms were scanned in US, CT and MRI devices. The size of test objects in the phantoms was measured from the US, CT and MRI images. RECIST, WHO and volume analyses were performed. Results: The smaller phantom size, simplified design and better test object CT contrast of the UTHSCSA multimodality tumor measurement phantom allowed scanning of the phantom in preclinical US, CT and MRI scanners compared with only limited preclinical scanning capability of Mark 1 and Mark 2 phantoms. For all imaging modalities, RECIST and WHO errors were reduced for UTHSCSA multimodality tumor measurement phantom (≤1.69 ± 0.33%) compared with both Mark 1 (≤ -7.56 ± 6.52%) and Mark 2 (≤ 5.66 ± 1.41%) phantoms. For the UTHSCSA multimodality tumor measurement phantom, measured tumor volumes were highly correlated with NIST traceable design volumes for US (R2 = 1.000, p < 0.0001), CT (R2 = 0.9999, p < 0.0001) and MRI (R2 = 0.9998, p < 0.0001). Conclusions: The UTHSCSA multimodality tumor measurement phantom described in this study can potentially be a useful quality assurance tool for verifying radiologic assessment of tumor size change during preclinical anti-cancer therapy testing with multiple imaging modalities.Keywords
This publication has 26 references indexed in Scilit:
- Semi-automated volumetric analysis of artificial lymph nodes in a phantom studyEuropean Journal of Radiology, 2011
- Semi-Automated Quantification of Hepatic Lesions in a PhantomInvestigative Radiology, 2009
- Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliperBMC Medical Imaging, 2008
- Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectivesThe Lancet Oncology, 2008
- Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and LimitationsRadioGraphics, 2008
- [Measurement of tumour response to cancer treatment: morphologic imaging role].2007
- Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial ct scan-based studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size.British Journal of Radiology, 2000
- Accuracy of Volume Measurements of Computed Tomography and Magnetic Resonance Imaging Phantoms by Three-Dimensional Reconstruction and Preliminary Clinical ApplicationInvestigative Radiology, 1994
- Volume determinations using computed tomographyAmerican Journal of Roentgenology, 1982